Sagimet Biosciences Inc (SGMT)

Dec 17, 2024

Sagimet Biosciences: A Rising Star in the Fight Against NASH with Promising Clinical Data for Denifanstat - mediahousepress

Dec 17, 2024

Dec 17, 2024

Sagimet Biosciences' SWOT analysis: promising NASH drug faces funding hurdles - Investing.com Australia

Dec 17, 2024

Dec 16, 2024

Sagimet Biosciences up 30% on strong clinical stage data - Mugglehead

Dec 16, 2024

Dec 15, 2024

Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans - Simply Wall St

Dec 15, 2024

Dec 11, 2024

(SGMT) On The My Stocks Page - Stock Traders Daily

Dec 11, 2024

Dec 09, 2024

Sagimet Biosciences (NASDAQ:SGMT) Research Coverage Started at Oppenheimer - Defense World

Dec 09, 2024

Dec 07, 2024

Sagimet Biosciences (NASDAQ:SGMT) Now Covered by Analysts at Oppenheimer - MarketBeat

Dec 07, 2024

Dec 06, 2024

Oppenheimer Initiates Coverage of Sagimet Biosciences (SGMT) with Outperform Recommendation - MSN

Dec 06, 2024

Dec 06, 2024

Sagimet started at outperform by Oppenheimer, MASH drug cited - MSN

Dec 06, 2024

Dec 06, 2024

Sagimet started at outperform by Oppenheimer, MASH drug cited (NASDAQ:SGMT) - Seeking Alpha

Dec 06, 2024

Dec 05, 2024

Oppenheimer sets $30 target on Sagimet Biosciences shares - Investing.com

Dec 05, 2024

Nov 30, 2024

How To Trade (SGMT) - Stock Traders Daily

Nov 30, 2024

Nov 26, 2024

Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire

Nov 26, 2024

Nov 26, 2024

Sagimet Biosciences to Present at Piper Sandler Healthcare Conference | SGMT Stock News - StockTitan

Nov 26, 2024

Nov 19, 2024

Sagimet Biosciences participates ik,on No - TipRanks

Nov 19, 2024

Nov 19, 2024

Sagimet Biosciences Inc. Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLDthe Liver Meeting 2024 - Marketscreener.com

Nov 19, 2024

Nov 19, 2024

HC Wainwright Reaffirms “Buy” Rating for Sagimet Biosciences (NASDAQ:SGMT) - Defense World

Nov 19, 2024

Nov 18, 2024

Sagimet Biosciences keeps stock target with Buy rating on phase 3 program - Investing.com

Nov 18, 2024

Nov 18, 2024

Sagimet Biosciences presents clinical denifanstat, preclinical FASN inhibitor da - TipRanks

Nov 18, 2024

Nov 18, 2024

Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLDThe Liver Meeting® 2024 - The Manila Times

Nov 18, 2024

Nov 18, 2024

Sagimet Biosciences Presents Clinical Denifanstat and - GlobeNewswire

Nov 18, 2024

Nov 18, 2024

Sagimet's Denifanstat Shows 49% Fibrosis Improvement in Phase 2b MASH Trial | SGMT Stock News - StockTitan

Nov 18, 2024

Nov 18, 2024

Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance

Nov 18, 2024

Nov 16, 2024

Sagimet Biosciences' (SGMT) Buy Rating Reiterated at HC Wainwright - MarketBeat

Nov 16, 2024

Nov 15, 2024

Steven Cohen's Strategic Acquisition in Sagimet Biosciences Inc - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

Hillhouse Capital Management's Strategic Reduction in Sagimet Bi - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

Baker Bros. Advisors LP Increases Stake in Sagimet Biosciences I - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $24.00 Consensus Price Target from Analysts - Defense World

Nov 15, 2024

Nov 14, 2024

Sagimet Biosciences Advances MASH Treatment with Denifanstat - TipRanks

Nov 14, 2024

Nov 14, 2024

Sagimet: More Than Just A MASH Drug Development Biotech (NASDAQ:SGMT) - Seeking Alpha

Nov 14, 2024

Nov 14, 2024

Sagimet Biosciences reports Q3 EPS (45c) vs (35c) last year - TipRanks

Nov 14, 2024

Nov 14, 2024

Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire

Nov 14, 2024

Nov 14, 2024

Sagimet Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 14, 2024

Nov 14, 2024

Sagimet's Denifanstat Earns FDA Breakthrough Status; Reports $170M Cash Position | SGMT Stock News - StockTitan

Nov 14, 2024

Nov 13, 2024

Ascletis Completes Enrollment of Phase III Trial of ASC40 Once-Daily Oral Tablet for Treatment of Acne - Marketscreener.com

Nov 13, 2024

Nov 12, 2024

UBS says Sagimet stock could steal the MASH spotlight from injectables - Investing.com Canada

Nov 12, 2024

Nov 12, 2024

Sagimet stock draws buy at UBS on MASH(SGMT:NASDAQ) - Seeking Alpha

Nov 12, 2024

Nov 12, 2024

SGMTSagimet Biosciences Inc. Series A Latest Stock News & Market Updates - StockTitan

Nov 12, 2024

Nov 12, 2024

Brokerages Set Sagimet Biosciences Inc. (NASDAQ:SGMT) Price Target at $24.00 - MarketBeat

Nov 12, 2024

Nov 12, 2024

Sagimet Biosciences (NASDAQ:SGMT) Coverage Initiated by Analysts at UBS Group - MarketBeat

Nov 12, 2024

Nov 12, 2024

Sagimet Biosciences initiated with a Buy at UBS - TipRanks

Nov 12, 2024

Nov 10, 2024

Sagimet Biosciences Insiders Benefit From Selling Stock At US$3.10 - Simply Wall St

Nov 10, 2024

Nov 08, 2024

Trend Tracker for (SGMT) - Stock Traders Daily

Nov 08, 2024

Nov 07, 2024

Sagimet Biosciences to Participate in the UBS Global Healthcare Conference - The Manila Times

Nov 07, 2024

Nov 04, 2024

Sagimet planning Phase 3 trials of denifanstat in MASH, MASLD - Liver Disease News

Nov 04, 2024